Experimental study finds new substances with higher specificity and therapeutic potential in multiple sclerosis

^{Karl Carlström, photo Stefan Zimmerman}

Karl Carlström (first author), Faiez al Nimer and Fredrik Piehl, from CMM (Fredrik Piehl Team), together with coauthors, published a study in which they found a new substance which could potentially be more specific for treating multiple sclerosis (MS) than currently used drugs. Dimethyl fumarate (DMF)/tecfidera is today a leading first-line treatment for relapsing-remitting MS worldwide. The researchers performed an experimental study using animal models, in which they compared DMF to other substances, measuring the protective effect on oligodendrocytes, the cells that are being injured and destroyed in MS.

More details can be found at ki.se (in Swedish). The paper was published in Neurotherapeutics.